Published in Obesity and Diabetes Week, December 4th, 2006
The European patent further strengthens Metabolex's intellectual property position surrounding metaglidasen, which Metabolex is now evaluating in a pivotal phase 2/3 trial of patients with type 2 diabetes. The company has 14 issued patents covering...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week